Hims and Hers Health Inc (HIMS) 옵션

Hims & Hers Health Inc (HIMS.NaE) shares are tumbling Tuesday on the heels of the company’s fourth-quarter financial results. Here’s what you need to know.

What Happened: Hims & Hers Health (HIMS.NaE) reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to Benzinga Pro. The company reported fourth-quarter earnings of 11 cents per share, in line with analyst estimates.

Total revenue was up 69% on a year-over-year basis. Subscribers grew to 2.2 million in the quarter, up 45% year-over-year. Gross margin was 77% in the fourth quarter, which came up short of analyst estimates of 78.4%, according to CNBC.

Hims & Hers Health (HIMS.NaE) shares have been on a tear since the company said it would begin selling compounded versions of GLP-1 injections last year. The stock fell more than 20% on Friday after the U.S. Food and Drug Administration removed semaglutide injections from the shortage list. Hims & Hers said this week that its GLP-1 offering brought in over $225 million in revenue in 2024.

“2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system,” said Andrew Dudum, co-founder and CEO of Hims & Hers Health (HIMS.NaE).

“In the coming years, we expect to further transform how individuals can improve their health with more comprehensive treatments, technologies that normalize unlimited follow up support, and tools that can eventually be exported beyond Hims and Hers, enabling even more Americans to access this care.”

See Also: DocuSign Boasts 13% Revenue Growth In Q4, Raises Full-Year Guidance Due To AI Momentum

Hims & Hers Health (HIMS.NaE) guided for first-quarter revenue of $520 million to $540 million. The company expects full-year 2025 revenue to be in the range of $2.3 billion to $2.4 billion versus estimates of $2.087 billion, according to Benzinga Pro.

Following the company’s quarterly results, Citigroup analyst Daniel Grosslight maintained Hims & Hers with a Sell and raised the price target from $25 to $27. Needham analyst Ryan MacDonald maintained a Buy rating and raised the price target from $31 to $61.

HIMS Price Action: Hims & Hers Health (HIMS.NaE) shares were down 19.6% at $41.15 at the time of publication Tuesday, according to Benzinga Pro.

Photo: Shutterstock.

Just slammed 20k in 36's myself. Love it.

This waaayyyyy overreacted to their reporting a weight loss drug. I just can't tell if the buyback is $35 or $29?

Buying the shares I sold at 57 back today 😁. I love these over reactions to good numbers and good guidance. Fundamentals have not changed here. Solid growth ahead for hims

Is this Jeopardy? OK, I'll play.....
What is the newest pump and dump?

HIMS, 10Q due MONDAY 2/24

NEWH

Mind boggling.

Great day!

$72 ouch for anyone short!

Weight loss made affordable nice play 

HIMS, new 52 week high

Truly incredible moves!

Shorts are getting wrecked! :)

$HIMS

HIMS holding a core at 13.50
Short % of Float (1/31/2025) 30.35%
Short % of Shares Outstanding (1/31/2025) 26.64%

$HIMS

OVER 41. Wow.

HIMS, new 52=high

Sharectile dysfunction? It can only stay up for so long.

hows is this 16% down premarket already today? what gives?

HIMS, just under the 52 week high

My luck was not paying attention to it too diligently...lol

I sold too soon, but to be fair, it already looks pricey.

Been one hell of a run. I took a few off. Been holding most from $6

Well, it sure hit $32 quickly enough. Now do we see the big breakout, or pullback? I should have taken my own advice here...

If you had played this stock right, it would have made for a nice roller coaster. I rode it once from $13 to $19. It looks like the next stop may be around $32.
Of course it is also the epitome of a high risk stock.

HIMS, new 52 week high

I wish for a world in which they are able to punish these laughable selloffs on some lukewarm excuse...
As seen in ADMA, HOOD, TSLA and here. Technically its fine... Practically what they are doing is an orchestrated maneuver to scam gullible investors living on buy/sell panic diet

HIMS new 52 week high

HIMS 10Q 11/4

IKT is having a fantastic run!

If you had played this stock right, it would have made for a nice roller coaster. I rode it once from $13 to $19. It looks like the next stop may be around $32.
Of course it is also the epitome of a high risk stock.

Wow

Good morning! In the latest GLP-1 news, the FDA reported last week that Eli Lilly’s weight loss and diabetes drug Mounjaro is no longer facing a shortage. This means pharmacy companies that have been compounding the medication, a process that uses the same ingredients and is only allowed in times of shortages, can no longer do so. Novo Nordisk’s Ozempic and Wegovy are not affected by this, and will likely continue to be distributed by compounding pharmacies, including Hims and Hers.

HIMS YTD

HIMS 10Q due AUGUST5

HIMS under $25

HIMS selling compounded GLP-1 despite the FDA warnings.
Compounding is allowed during shortages, but there may be issues with supplier?
Compounded drug is not FDA tested or approved.
Possible short candidate if it heads higher?

HIMS new 52 week high

HIMS new 52 week high

HIMS new 52 week high

God Bless Israel!

God Bless Israel.

Just sold my shares after learning about the dirt bag CEO. Hope the company tanks.

Share holders woke up to limp one, will have to take some viagra to get a pump.

HIMS..... From 16.21 to 20.45 in five days is good enough for me. Adios and GLTA

HIMS new 52 week high

HIMS.....

It's selling off on being down graded, you would have to be a total fool selling $15 puts at $0.05.

HIMS new 52 week high
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

~RIPPn on nice beat

~bought the 5/10 18.5 calls @.07c